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From the Northern Institute for Cancer Research,* Faculty of
Medical Sciences, and the Department of Pathology,§ University
of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom;
the Department of Pathology,† Faculty of Medicine, Sohag
University, Sohag, Egypt; and the Breast Cancer Unit,‡
Department of Surgery, Royal Victoria Infirmary, Newcastle upon
Tyne, United Kingdom
The trefoil protein TFF3 stimulates invasion and an-
giogenesis in vitro. To determine whether it has a role
in breast tumor metastasis and angiogenesis, its levels
were measured by immunohistochemistry in breast
tissue with a specific monoclonal antibody raised
against human TFF3. TFF3 is expressed in normal
breast lobules and ducts, at higher levels in areas of
fibrocystic change and papillomas, in all benign
breast disease lesions, and in 89% of in situ and in
83% of invasive carcinomas. In well-differentiated tu-
mor cells, TFF3 is concentrated at the luminal edge,
whereas in poorly differentiated cells polarity is in-
verted and expression is directed toward the stroma.
Expression was high in well-differentiated tumors
and was associated significantly with low histological
grade and with estrogen and progesterone receptor
expression, accordant with induction of TFF3 mRNA
by estrogen in breast cancer cells. Paradoxically, TFF3
expression was associated with muscle, neural, and
lymphovascular invasion and the presence and
number of involved lymph nodes, and it was an
independent predictive marker of lymphovascular
invasion and lymph node involvement. Consistent
with an angiogenic function, TFF3 expression cor-
related strongly with microvessel density evaluated
with CD31 and CD34. In conclusion, TFF3 is ex-
pressed in both the normal and diseased breast.
Although associated with features of good progno-904sis, its profile of expression in invasive cancer is con-
sistent with a role in breast tumor progression and
tumor cell dissemination. (Am J Pathol 2012, 180:
904–916; DOI: 10.1016/j.ajpath.2011.11.022)
Improvements in the early diagnosis and clinical man-
agement of breast cancer have led to an impressive
reduction in mortality notwithstanding which 500,000
people die every year as a direct result of disseminated
disease. During carcinogenesis, neoplastic cells acquire
the ability to migrate, invade, and metastasize either di-
rectly into neighboring tissues or via the neural network,
lymphatic system, or vasculature to more distant sites. In
breast cancer, malignant cells can invade locally to the
underlying muscle or overlying skin or can escape
through the neural sheath or via the lymph or blood ves-
sels. The presence of tumor metastases in the axillary
lymph nodes is an important part of clinical staging and
prediction of prognosis. It is accepted that the existence
of metastases in regional lymph nodes is not a precursor
of but a manifestation of more distant spread. Distant
metastases occur most commonly in bone, followed by
lung, liver, and brain. Understanding of the underlying
biology of breast cancer and breast cancer metastasis
remains obscure yet is increasingly relevant clinically
with the move toward stratified medicine and therapeutic
monitoring.
Systemic therapies are important in the treatment of
both early stage and advanced breast cancers. Endo-
crine therapies, which have been the mainstay of breast
cancer therapy, exploit the dependence of tumor cells on
estrogens and include partial and pure antiestrogens and
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likely to respond to endocrine therapies are identified by
the presence of the estrogen receptor , which is a req-
uisite for estrogen action, and the progesterone receptor,
which is induced by estrogen.
Trefoil proteins are small, secreted proteins that are
co-expressed with mucins by epithelia and are thought to
be important in normal mucosal protection and repair.1,2
The three human members of the trefoil factor family,
TFF1, TFF2, and TFF3, are characterized by the presence
of a conserved 41- to 42-amino acid residue trefoil do-
main with distinctive structure. TFF1 and TFF3 contain
one trefoil domain, whereas TFF2 contains two. TFF3 has an
extra trefoil domain cysteine residue that forms intermolec-
ular disulfide bonds.3 The structure of dimeric TFF3 is con-
siderably more compact than that of dimeric TFF1.3–5
The normal functions of trefoil proteins are thought to
center on their role in mucosal protection, namely inter-
actions with mucins and stimulation of cell motility.1,2
TFF3 has been found to stimulate cellular invasion in vitro
and to have angiogenic activity.6,7 The role of trefoil pro-
teins in cancer is controversial. TFF1 is thought to be a
tumor suppressor in gastric cancer,8 whereas in other tu-
mors, including breast, prostate, and bladder, trefoil factor
expression has been considered to be ectopic.1 Their ex-
pression has been reported to be predictive both of better
survival9,10 and of a more aggressive phenotype.11–14
TFF1 was discovered first as an abundant estrogen-
regulated molecule in breast cancer cells, whereas TFF2
is expressed only at very low levels in breast cancer
cells.15–18 In 1997, TFF3 mRNA was detected by in situ
hybridization in normal breast, in benign and in situ lesions,
and in 31 invasive carcinomas19 and was shown to be
induced by estrogen and inhibited by antiestrogens in es-
trogen-responsive breast cancer cells.20 Subsequently,
large expression microarray studies identified TFF3 as
one of the genes whose expression is most closely as-
sociated with expression of estrogen receptor .21,22 The
expression and role of TFF3 protein in human breast
tissue have not been studied.
We report that TFF3 protein is expressed in the normal
breast, benign breast disease, and in situ carcinoma and
that its expression is lost in some invasive breast carci-
nomas. We provide evidence that, although TFF3 protein
expression is higher in well-differentiated tumors and is
associated with markers of estrogen responsiveness,
TFF3 has a more sinister role in breast cancer invasion
and metastasis.
Materials and Methods
Collection of Tissue Samples
Ethical permission for the studies was obtained from the
Joint Newcastle Health Hospitals and University of New-
castle on Tyne Ethical Committee. Samples were collected
from archived material of patients who presented sequen-
tially between 2002 and 2004. Tissue was selected, and
1-mm cores of tissue were embedded in tissue microarrays.
Duplicate cores of tissue were taken from different blocksand arrayed in separate paraffin blocks. In total, 34 samples
of normal breast, 86 benign breast lesions, 116 in situ car-
cinomas, 266 invasive carcinomas, and 76 involved lymph
nodes were included in the study. In addition, whole sec-
tions of normal breast tissue from 40 women between the
ages of 18 and 39 were analyzed.
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded breast tis-
sue were deparaffinized and rehydrated. They were in-
cubated in 0.5% hydrogen peroxide for 10 minutes to
block endogenous peroxide activity. Antigen retrieval
was with trypsin for 10 minutes at room temperature, in a
10 mmol/L citrate buffer, pH 6.0, in a pressure cooker for
0.5 to 3 minutes or in a microwave for 2  5 minutes. After
antigen retrieval, the tissue was washed in Tris-HCl, pH
7.6, buffered saline and 1% Tween 20. The tissues were
incubated with a specific anti-TFF3 monoclonal antibody
(manuscript in preparation) raised against correctly
folded human TFF3 protein,3,4 a specific anti-TFF1 mono-
clonal antibody raised against correctly folded human
TFF1 protein,23 anti-CD31 (JC70A; Dako UK Ltd., Ely,
Cambridgeshire, UK), anti-D34 (QBend-10; Dako UK
Ltd.), or anti-Ki-67 (MIB-1; Dako UK Ltd.) diluted in Tris-
buffered saline and 1% Tween 20 at room temperature and
then with the Universal Probe [X-Cell Plus Polymer HRP
(horseradish peroxidase) detection kit; A. Menarini Diag-
nostics, Firenze, Italy] at room temperature and finally with
HRP-Polymer (A. Menarini Diagnostics). The brown colori-
metric reaction was developed by incubation with 3,3= di-
aminobenzidine, and the sections were counterstained with
hematoxylin.
Scoring and Statistical Analysis
The immunohistochemistry results were analyzed to gen-
erate a histoscore that combines the intensity of the im-
munoreaction with the number of positive cells. One thou-
sand cells were scored individually as negative, weakly
positive, moderately positive, or strongly positive. These
four categories are weighted as 0, 0.1, 0.3, and 1.0, re-
spectively, in recognition of the range of intensities of the
immunoreaction. The histoscores varied between 0 and
1000. A sample of normal human colonic mucosa was in-
cluded in all immunohistochemical experiments to serve as
a reference of the intensity of the immunoreaction. The final
histoscore is the mean of scores from the two sections
for each sample. The concordance between the two
values was strong and significant (Spearman’s  cor-
relation, P  0.001).
The results were analyzed statistically with the SPSS-PC
package version 17 (SPSS Inc., Chicago, IL). Probabilities
of 0.05 were considered statistically significant. The sta-
tistical significance of differences observed was analyzed
by Kruskal-Wallis II or Mann-Whitney U tests and of cor-
relations by Pearson’s correlation or Spearman’s  corre-
lation. To adjust for potential confounding variables and
to single out independent predictors, a multivariate anal-
ysis was undertaken. The different histoscores were
scaled, and the predictive ability of the continuous vari-
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refined by stepwise selection.
Results
Expression of TFF3 Protein in Normal Breast
Epithelium
The expression of TFF3 protein was characterized in nor-
mal breast tissue from 34 premenopausal and perimeno-
pausal women. There was strong TFF3 immunoreaction
in the cytoplasmic compartment of normal breast lobular
epithelial cells which showed frequently clear cellular
polarity (Figure 1, A and D). TFF3 protein was localized
toward the luminal borders of the acini and was often
absent at the basal membrane, which is consistent with
TFF3 being secreted from the acini into the lumina of the
lobules. No immunoreaction was observed in myoepithe-
lial or stromal cells. TFF3 expression was detected in
most of the normal breast lobules. TFF3 expression was
detected also in epithelial cells of the intralobular and
interlobular ducts (Figure 1B) and in the main lactiferous
duct (Figure 1C). TFF3 was concentrated toward the lu-
mina of the polarized epithelial cell monolayers. TFF3 has
been measured in human milk,24 but the breast lobules in
which TFF3 expression was detected in the present study
were not from lactating women. These results show that
TFF3 is synthesized in the normal nonlactating breast and
are consistent with it being secreted from the breast
epithelial cells and having a role in maintenance of the
epithelial integrity of the lobular and ductal lumina.
We investigated the possibility that expression of TFF3
in the normal breast lobule might depend on cyclical
changes that occur during the menstrual cycle. The mor-
phological features of the breast which change during
the menstrual cycle were assessed by histologic param-
eters.25,26 The breast lobules in the two cases in which
TFF3 expression was not detected were in the early fol-
licular phase that is characterized by low circulating lev-
els of estrogen and progesterone. Late follicular phase
coincides with an increase in circulating estrogens and is
characterized by clear acinar formation with distinct lu-
minal cells. After ovulation and resultant increased cir-
culating progesterone, the breast enters the early lu-
teal phase, and lumina become enlarged compared
with previous phases. The secretory phase is charac-
terized by apocrine secretion from the luminal epithe-
lial cells. The fifth, menstrual phase is associated with
estrogen and progesterone withdrawal, and apocrine
secretion abates.25 A trend toward elevated TFF3 ex-
Figure 1. Expression of TFF3 in normal and diseased human breast. Section
anti-human TFF3 mouse monoclonal IgG as described in Materials and Me
lobules (A and D); an interlobular duct (B); a lactiferous duct (C); sclerosin
ductal carcinoma in situ of solid, comedo, and cribriform types (I, J, and K)
invasive lobular carcinoma (P); medullary (Q), metaplastic (R), and cribrifor
and invasive ductal carcinoma of no specific type with cytological atypia and
shown. Arrows indicate malignant epithelial cells with TFF3 expression abs
intense gray), and strongly positive (M–O; black). Examples of cells in which
the stroma (blue arrows) are indicated. Multinucleated cells in a carcinoma wit
atypical (X) and in a ductal carcinoma of no specific type (M) are indicated (repression was observed in the late follicular phase com-
pared with the early follicular phase, but the difference
was not statistically significant.
The potential association between TFF3 expression
and morphological changes that occur in breast lobular
epithelial cells during the menstrual cycle was examined
further in breast lobules of 40 younger women, aged
between 18 and 39 years. Cytoplasmic expression of
TFF3 in breast luminal epithelial cells was higher during
late follicular and early luteal phases of the menstrual
cycle (median, 560 and 430) when estrogen levels are
higher than during the early follicular or late luteal phases
(median, 25 and 110) when estrogen levels are low
(Kruskal-Wallis II test, P  0.01). TFF3 immunoreaction
was strong within the apocrine secretions of luminal cells
in the secretory phase. During the menstrual phase, TFF3
immunoreaction was restricted mainly to the apical edge
of the cells and residual secretory material within the
lumina. The results indicate that there is an association
between TFF3 expression in breast lobular epithelial cells
and the stage of menstrual cycle.
Alterations in TFF3 Expression in Benign Breast
Lesions
TFF3 was expressed in all 86 benign breast lesions ex-
amined (Figure 1, E–H). As with normal breast tissue,
TFF3 protein was expressed only by the epithelial cells.
Even in cases of sclerosing adenosis, in which the in-
creased number of involved lobules are compressed and
obliterated by stromal fibrosis (Figure 1E), the myoepi-
thelial cells did not express TFF3. The intensity of the
immunoreaction varied considerably among the 14 cases
of sclerosing adenosis studied from almost undetectable
to relatively strong. In the 10 fibroadenomas studied,
TFF3 expression was detected always, but the intensity of
the immunoreaction varied markedly between cells (Fig-
ure 1F). Fibroadenomas in which the glandular compo-
nent was dominant tended to express more TFF3 than
those in which the stromal component was dominant. In
the six intraductal papillomas (Figure 1G), a higher pro-
portion of cells contained detectable levels of TFF3 than
in fibroadenomas or cases of sclerosing adenosis. In
fibrocystic disease (Figure 1H), all epithelial cells present
in areas of fibrocystic change expressed detectable
TFF3, and the immunoreaction was strong in most. TFF3
was detected always in the cytoplasm, and the immuno-
reaction was sometimes granular in appearance. When
acini were visible, TFF3 was concentrated toward the
lumina, and the immunoreaction was strong in areas in
uman breast tissue were analyzed by immunohistochemistry with a specific
epresentative examples of the immunoreaction with normal human breast
sis (E); a fibroadenoma (F); a ductal papilloma (G); fibrocystic change (H);
carcinoma in situ (L); invasive ductal carcinoma of no specific type (M–O);
omas (S); a phyllodes tumor (T); tubular (U) and mucinous (V) carcinomas;
cleated cells (W) and with cytological atypia and numerous mitoses (X) are
nd N; white), weakly positive (M–O; pale gray), moderately positive (M–O;
pression is polarized either away from the lumen (pink arrows) or away from
nent cytologic atypical (W), and mitotic cells in a carcinoma with mild cytologic
s). Original magnification: 200 (A, C, F–X); 400 (E), and 630 (B and D).s from h
thods. R
g adeno
; lobular
m carcin
multinu
ent (M a
TFF3 ex
h promi
d arrow
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apparent. The luminal release of TFF3 was particularly
evident in apocrine metaplasia. TFF3 expression was
especially high in cells that exhibit apocrine metaplasia
within areas of fibrocystic change but was absent in
squamous metaplasia.
A
B
CTFF3 expression in the normal breast tissues and in
benign breast lesions was quantified to generate a his-
toscore (Figure 2A). Four cases each of sclerosing ad-
enosis (29%), fibroadenoma (40%), and papilloma (67%)
and 53 cases of fibrocystic change (95%) had high his-
toscores. TFF3 expression is significantly higher in
papilloma of the breast and in areas of fibrocystic
change than in normal breast tissue (Mann-Whitney
U-test, P  0.01 and P  0.001, respectively). TFF3
expression in papilloma and in fibrocystic change is
higher also than in sclerosing adenosis and fibroade-
noma (Kruskal-Wallis II test, P  0.001).
Expression of TFF3 in in Situ Malignant Breast
Lesions
TFF3 was detected in 93 of the 106 cases (88%) of ductal
carcinoma in situ studied, which comprised 50 of mixed
histologic type, 33 solid, 17 comedo, 4 cribriform, and 2
papillary tumors (Figure 1, I–K). TFF3 immunoreaction
was generally strong and, where cellular polarity was
evident, was concentrated at the luminal edge but was
distributed evenly throughout the cytoplasm in nonpolar-
ized malignant epithelial cells. No statistically significant
differences were observed in TFF3 expression between
subtypes of carcinoma in situ (Figure 2B) or between
different grades; 81 lesions were of high grade, 13 of
intermediate grade, and 12 of low grade. TFF3 immuno-
reaction was detected in all cases of lobular carcinoma in
situ (Figure 1L).
Expression of TFF3 in Invasive Malignant Breast
Lesions
TFF3 was detected in 215 of 266 invasive tumors (Figure
1). The immunoreaction was cytoplasmic with a tendency
toward perinuclear condensation in some cells, consis-
tent with the concentration of the TFF3 protein in the Golgi
apparatus before its secretion. Most of the immunore-
active tumor cells were moderately to strongly positive.
TFF3 was not detected in the surrounding stromal, endo-
thelial, inflammatory, or muscle cells. Malignant cells in
tumors with strong TFF3 expression were scattered dif-
fusely throughout the stroma (Figure 1O), whereas those
Figure 2. Association of TFF3 expression with differentiation in diseased
human breast. TFF3 expression was measured by immunohistochemistry in
34 samples of normal breast tissue, 14 lesions of sclerosing adenosis (S.
aden.), 10 fibroadenomas (F. aden.), 6 ductal papillomas (Papill.), and 56
cases of fibrocystic change (FCC), and the relative levels of TFF3 expression
were determined by derivation of a histoscore as detailed in Materials and
Methods (A). Expression was measured also in 116 in situ malignant breast
lesions (B) and in invasive breast tumors (C) from 266 patients. The hori-
zontal bars represent the median values, the boxes indicate the range of the
second and third quartiles of the data, and the whiskers represent the range
of all of the data, that is, the sample minimum and the sample maximum. x
The numbers refer to the number of cases analyzed for each type of lesion.
The stars represent extreme values that are more than three times further
from the second or third quartile than the difference between the second or
third quartile and the median. Com., comedo; Cribrifo., cribriform; IDC NOS,
invasive ductal carcinoma of no specific type; ILC, invasive lobular carci-
noma; LCIS, lobular carcinoma in situ; Papillar., papillary.
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cluster or aggregate together within the stroma (Figure 1,
M and N). Within these clusters, malignant cells with
higher TFF3 expression were concentrated on the edges
of the cell aggregates and in some instances had polar-
ized TFF3 immunoreaction that was more intense toward
the stromal edge of the tumor cell.
TFF3 expression in the 204 invasive ductal carcinomas
of no specific type (Figure 1, M–O) ranged from unde-
tectable (not shown) to very high. In tumors with lower
TFF3 expression (Figure 1, M and N), the intensity of the
immunoreaction varied considerably between individual
malignant cells. In tumors with very high TFF3 expression
(Figure 1O), most or all of the malignant cells were in-
tensely immunoreactive. Variable levels of TFF3 expres-
sion were detected also in 31 cases of invasive lobular
carcinoma (Figure 1P). Signet ring cells and those with a
leading edge within lobular carcinomas had high TFF3
expression.
TFF3 was not detected in four cases of medullary car-
cinoma (Figure 1Q), and expression was generally low in
the eight cases of the other special types of invasive
ductal carcinoma. These comprised three micropapillary,
two metaplastic (Figure 1R), one apocrine, and one
cribriform (Figure 1S) carcinoma and one phyllodes tu-
mor of the breast (Figure 1T). TFF3 expression is signif-
icantly higher in tubular (Figure 1U) and mucinous (Fig-
ure 1V) carcinomas, which are well differentiated and
have a favorable prognosis, than in all other types of
invasive breast carcinoma (Figure 2C, Kruskal-Wallis II
test, P  0.01). In mucinous carcinoma, the intracellular
mucus and occasional extracellular mucus was immuno-
reactive for TFF3.
Association of TFF3 Protein with Differentiation
and Estrogen Response in Malignant Breast
Epithelial Cells
We investigated whether TFF3 expression is associated
with histological grade of the tumors. All grade 1 tumors
express detectable TFF3, but a third of grade 3 tumors
contain no TFF3 protein (Figure 3A). The median values
for TFF3 expression were 420 for grade 1 tumors, 340 for
grade 2 tumors, and only 100 for grade 3 tumors; there is
a significant negative association between tumor grade
and TFF3 protein expression (Spearman’s  coefficient,
P  0.01). Thus, TFF3 expression is significantly lower in
high-grade breast tumors than in low-grade tumors
(Kruskal-Wallis II test, P  0.001).
Greater than 70% of the tumors in which TFF3 expres-
sion was not detected was grade 3. To investigate if there
was coordinate loss of expression of the paralagous tre-
foil protein, TFF1 in these tumors, TFF1 expression was
analyzed by immunohistochemistry with an antibody
raised against TFF1 protein.23 TFF1 immunoreaction was
detected in only 2 of the 36 grade 3 tumors in which TFF3
expression was absent. These results indicate that there
is coincident loss of TFF3 and TFF1 expression in breast
cancer, which is consistent with interconnectivity of reg-
ulation of the TFF1 and TFF3 genes in breast cancer cells.A
B
C
Figure 3. Association of TFF3 expression with pathological indicators of
good prognosis. TFF3 expression determined by derivation of a histoscore
was compared in tumors of different histologic grade (A) as described in the
legend to Figure 2. The distribution of TFF3 expression in tumors with
different Allred scores for estrogen receptor (B) and progesterone receptor
expression (C) are shown. Data points for samples with identical values are
superimposed in the figure when there are more than three such data points.
Horizontal bars indicate the median values of TFF3 expression. The sloping
line is the regression line through the data.
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ance, including a high nuclear-to-cytoplasmic ratio and ab-
sence of tubular differentiation, with cytologic atypia tended
to express less TFF3 protein (Figure 1W), whereas TFF3
was expressed at markedly higher levels in invasive breast
cancer types that are characterized by good differentiation:
tubular and mucinous carcinomas. These observations
coupled with the finding that TFF3 is secreted by normal
breast acini suggest that the negative association of TFF3
expression with tumor grade is explained in part by its
association with good differentiation.
Another possible reason for the strong negative asso-
ciation between TFF3 expression and tumor grade is that
TFF3 expression is related to the proportion of mitotic
cells. Cases with multinucleated cells or with a high mi-
totic incidence tended to express less TFF3 protein (Fig-
ure 1, W and X). Cases with a low mitotic incidence
tended to express more TFF3, and TFF3 was not detect-
able in dividing cells within tumors that do express TFF3
(Figure 1M). These observations of a negative associa-
tion between TFF3 expression and mitotic incidence are
exemplified by the absence of TFF3 protein in medullary
carcinomas (Figure 1Q) that have a high mitotic index
and by its higher level in tubular carcinomas (Figure 1U)
that have a low mitotic index.
An association between expression of Ki-67, a nuclear
nonhistone protein, and mitotic index has been reported
by most researchers.27 To investigate further the potential
relationship between TFF3 expression and proliferation of
breast cancer cells, we measured expression of the pro-
liferative biomarker Ki-67 by immunohistochemistry and
investigated the association between TFF3 expression
and Ki-67 expression. A strong negative correlation was
observed between TFF3 protein and Ki-67 expression
(Spearman’s  correlation, P  0.001), which agrees with
the observations that tumors that express more TFF3
have low mitotic indices and is consistent with TFF3 ex-
pression militating against cell division in malignant
breast epithelial cells.
TFF3 mRNA is induced by estrogen in estrogen-
responsive breast cancer cells,20 and we investigated
whether TFF3 protein expression is associated with
estrogen receptor expression (Figure 3). Estrogen and
progesterone receptors were measured during routine
pathologic diagnosis and scored on the Allred scale from
0 to 8.28 The clinical decision to offer endocrine therapy
is based on a cutoff value of 3.0. TFF3 expression was not
detected in most of the tumors that do not express the
estrogen receptor. A strong positive correlation was ob-
served between estrogen receptor and TFF3 protein ex-
pression (Figure 3B, Pearson’s correlation, P  0.0001)
and between progesterone receptor and TFF3 protein
expression (Figure 3C, Pearson’s correlation, P 
0.0001).
Association between TFF3 Expression and
Tumor Cell Infiltration
The possible involvement of TFF3 in local invasion was
considered first by evaluating TFF3 expression in meta-static cells. Tumor cells infiltrating underlying muscle ex-
pressed high levels of TFF3 (Figure 4, A and B). In cases
with local epidermal invasion, the invading tumor cells
often expressed high amounts of TFF3 (Figure 4C). TFF3
expression was detected in 9 of 10 cases of Paget dis-
ease of the nipple and was high in the majority (Figure
4D). Extremely high levels of expression of TFF3 were
found in malignant epithelial cells involved in canceriza-
tion of the lobule (Figure 4, E and F), which is character-
ized by the migration of malignant cells from the original
ductal carcinoma in situ lesion to the associated lobules
without penetration of the myoepithelial cell layer. These
observations led us to investigate whether tumors with overt
locoregional invasion (Figure 5A) express higher levels of
TFF3 than tumors without locoregional invasion. TFF3 ex-
pression was significantly higher in primary tumors associ-
ated with muscle invasion (Mann-Whitney U-test, P  0.05)
and in tumor cells in Paget disease (Mann-Whitney U-test,
P  0.05) but not in tumors with skin invasion.
High TFF3 expression was observed in tumor cells invad-
ing the neural sheath (Figure 4, G and H). We investigated
whether high expression of TFF3 by tumor cells is associ-
ated with escape by the neural route. High TFF3 expression
was observed in most cases in which neural invasion had
been reported (Figure 5A) and was significantly higher than
expression in invasive breast tumors without locoregional
invasion (Mann-Whitney U-test, P  0.05).
Eighty-two of the 225 invasive tumors in which lympho-
vascular invasion was evaluated histologically by the
presence of visible tumor cells within the tumor lymph or
blood vessels showed evidence of lymphovascular inva-
sion. High TFF3 expression was observed in tumor cells
entering the lymphovascular system (Figure 4I). The ex-
pression of TFF3 in tumor cells of breast cancers in which
intravasation of lymph and blood vessels was evident
was higher than in tumor cells of cases in which intrava-
sation was absent (Figure 5B, Mann-Whitney U-test, P 
0.05). The ability of TFF3 expression in the primary tumor
to predict any form of locoregional invasion, whether into
muscle, skin, or via neurovascular bundles, was consid-
ered also. TFF3 expression was associated significantly
with the presence of any type of invasion (Figure 5C,
Mann-Whitney U-test, P  0.05).
The association of TFF3 protein expression with low
histologic grade (Figure 3A) might obscure evaluation of
its positive association with metastasis. We determined
therefore the association between TFF3 expression and
the presence of lymphovascular, or the presence of any
form of invasion, within tumors of each histologic grade.
The association between TFF3 expression and lympho-
vascular invasion in each tumor grade is shown in Figure
5D. Expression of TFF3 appears higher in tumors with
associated lymphovascular invasion than in tumors with-
out associated lymphovascular invasion in all tumor
grades and reaches statistical significance in grade 3
tumors; high-grade tumors that express low levels of
TFF3 are much less likely to invade the lymphovascula-
ture (Mann-Whitney U-test, P  0.013). The association
between higher TFF3 expression and any form of inva-
, H–L, P
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statistical significance in grade 1 and grade 2 tumors
(Mann-Whitney U-test, P  0.057 and P  0.091, re-
spectively) and was highly significant for grade 3 tu-
mors (P  0.01).
A B
E F
I J
M N
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Figure 4. Expression of TFF3, CD31, and CD34 in invasive breast cancer. Se
a specific anti-human TFF3 mouse monoclonal IgG as described in Materia
invading muscle (A and B) and skin (C), of Paget disease of the nipple (D), of
(G and H), and the lymphovasculature (I) are shown. An example of TFF3 e
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AJP March 2012, Vol. 180, No. 3does not or does predict axillary lymph node involve-
ment.9,29 Histologic assessment of the presence of
breast cancer cells in the axillary lymph nodes was avail-
able for 201 cases of invasive breast cancer of which 84
had involved lymph nodes. TFF3 expression was higher
A
B C
Din primary tumor cells in tumors with associated involved
lymph nodes than in tumors without lymph node me-
tastases (Figure 6A, Mann-Whitney U-test, P  0.05),
and higher TFF3 expression is associated with a larger
number of involved lymph nodes (Pearson’s correla-
tion, P  0.05).
The levels of TFF3 expression in the primary tumor and
in the corresponding metastatic cells in the lymph nodes
are associated strongly (Figure 6C, Pearson’s correlation,
P  0.0001), and, in turn, expression in the metastatic
tumor cells within the lymph nodes is maintained in ma-
lignant cells in the perinodal fat (Pearson’s correlation,
P  0.001). Although these correlations are highly signif-
icant, it appeared that there was an increase in TFF3
expression as the tumor cells moved along the metastatic
cascade (Figure 6, B and C) from the primary tumor
(Figure 4J) to the axillary lymph node (Figure 4K) to the
perinodal fat (Figure 4L). TFF3 protein expression is as-
sociated positively with this metastatic progression
(Spearman’s  correlation, P  0.0001) and is higher in
tumor cells within the involved lymph nodes than in the
primary tumor and is increased further in tumor cells in
the perinodal fat that have evaded the lymph node cap-
sule (Figure 6, B and C, Kruskal-Wallis II test, P 
0.0001). These observations suggest that there is a se-
lection for higher TFF3 expression as the tumor cells
move to more distal metastatic sites and are consistent
with TFF3 playing an active role in metastasis.
Association of TFF3 Expression with
Angiogenesis
It has been reported that TFF3 stimulates angiogenesis.7
We considered the possibility that stimulation of a tumor
vasculature may be one way in which TFF3 promotes
lymphovascular invasion of malignant breast epithelial
cells. Expression of the endothelial cell markers CD31
and CD34 was measured by immunohistochemistry and
the density of immunoreactive blood vessels was calcu-
lated as described in Materials and Methods. Tumors with
an inflammatory reaction, granulation tissue, tumor ne-
crosis, tumor sclerosis, or large areas of mucin were
excluded from this analysis. CD34 expression gave a
higher estimate of the blood vessel density than CD31,
but there was a strong positive correlation between the
density of microvessels assessed with the two markers
Figure 5. Association of TFF3 expression with locoregional metastasis. TFF3
expression determined by derivation of a histoscore as detailed in Materials
and Methods in invasive tumors with different types of locoregional infiltra-
tion or with neural invasion is compared with TFF3 expression in all evalu-
able invasive tumors (A). TFF3 expression is compared between tumors
without (L.V.Inv.) or with lymphovascular invasion (L.V.Inv.) (B) and
between tumors with no infiltration (Inv.) and with any form of infiltration
(Inv.) (C). TFF3 expression was compared between tumors of different
histologic grade in which lymphovascular invasion was not detected
(LVI) and tumors in which it was (LVI) (D). The horizontal bars represent
the median values, the boxes indicate the range of the second and third
quartiles of the data, and the whiskers represent the range of all of the data.
The numbers refer to the number of cases analyzed for each type of lesion.
The circles represent outliers of 1.5 times, and the stars represent extreme
values of 3.0 times further from the second or third quartile than the
difference between the second or third quartile and the median.
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larity had relatively lower levels of TFF3 expression (Figure
4, M–P) than tumors with high vascularity (Figure 4, Q–T).
High TFF3 expression was associated positively with blood
vessel density as evaluated with both CD31 (Pearson’s cor-
relation, P  0.05) and CD34 (Pearson’s correlation, P 
0.01) endothelial markers. This finding is consistent with the
hypothesis that TFF3 stimulates angiogenesis in vivo.
Predictive Value of TFF3 as a Biomarker of
Breast Cancer Metastasis
At diagnosis, several pathologic and clinical factors, in-
cluding lymphovascular invasion and lymph node status,
contribute to clinical staging and inform clinical manage-
A
C
B
Figure 6. Association of TFF3 expression with lymph (L) node metastasis.
TFF3 expression determined by derivation of a histoscore as detailed in
Materials and Methods was compared in tumor cells from tumors without
and with associated involved lymph nodes (A) and in tumor cells in invasive
primary tumors, in involved lymph nodes, and in the perinodal (P.N.) fat (B).
The horizontal bars represent the median values, the boxes indicate the
range of the second and third quartiles of the data, and the whiskers repre-
sent the range of all of the data. The numbers refer to the number of cases
analyzed for each type of lesion. The circle represents an outlier value that is
1.5 times further from the second quartile than the difference between the
second quartile and the median. The association between TFF3 expression in
invasive tumor cells in the primary tumors and in the associated involved
lymph nodes is shown (C).ment and evaluation of prognosis. If TFF3 is important in
breast cancer invasion and metastasis, it might be ex-
pected to be a predictor of lymphovascular invasion and
lymph node metastasis. We evaluated the potential of
TFF3 as an effective predictive biomarker of lymphovas-
cular invasion and of lymph node metastasis by simple
logistic regression analysis and its relative importance by
multivariate binary logistic regression analysis. Binary lo-
gistic regression modeling is a multivariate technique that
allows the probability of a defined outcome to be esti-
mated by analysis of several parameters, including clin-
icopathologic features and molecular biomarkers.
In univariate analysis, TFF3 was a statistically signifi-
cant predictor of lymphovascular invasion (P  0.05).
Multivariate binary logistic regression analysis found that
tumor grade had the greatest ability to predict the pres-
ence of lymphovascular invasion amongst all of the fac-
tors considered (P  0.001 to 0.004), followed closely by
TFF3 (P  0.001). None of the other factors considered,
age, tumor size, tumor type, estrogen receptor status,
progesterone receptor status, CD31 expression, or
CD34 expression, made a significant contribution to
the prediction.
The regression equations were as follows. For Grade 1
tumors, Z  0.389  0.156 (TFF3 expression) 
(1.335). For Grade 2 tumors, Z  0.389  0.156 (TFF3
expression)  (0.815). For Grade 3 tumors, Z  0.389 
0.156 (TFF3 expression)  0.
TFF3 expression predicted lymph node metastasis as
a univariate biomarker (P  0.05). The ability of the nine
variables, age, tumor type, tumor size, tumor grade, es-
trogen receptor status, progesterone receptor status, mi-
crovessel density evaluated by CD31 and CD34, and
TFF3 expression, to predict lymph node metastasis was
tested by multivariate binary logistic regression analysis.
Tumor size (P  0.001), tumor grade (P  0.002 – 0.03),
and TFF3 (P  0.004) were retained in the model.
The regression equations were as follows. For Grade 1
tumors, Z  1.093  0.149 (TFF3 expression)  0.022
(tumor size)  (1.231). For Grade 2 tumors, Z  1.093 
0.149 (TFF3 expression)  0.022 (tumor size)  (1.092).
For Grade 3 tumors, Z  1.093  0.149 (TFF3 expres-
sion)  0.022 (tumor size)  0.
These analyses show that TFF3 expression is an inde-
pendent predictive biomarker of both lymphovascular in-
vasion and lymph node metastasis and that it has greater
predictive power than the other molecular markers ana-
lyzed.
Discussion
This is the first study of TFF3 protein expression in the
human breast. Our results establish that TFF3 protein is
present in normal breast epithelial cells; its cellular loca-
tion indicates that it is secreted into the lumina of breast
lobules and ducts. By analogy to the function of trefoil
proteins in other tissues, the function of TFF3 in the nor-
mal human breast may be to protect and maintain the
integrity of the epithelial surface. The other single domain
trefoil protein TFF1 is expressed also by normal breast
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cell is one of very few normal cell types in which TFF1 and
TFF3 are co-expressed.19
TFF3 protein is expressed in most of the benign and
malignant breast lesions studied. A strong association
was observed between TFF3 expression and tumor dif-
ferentiation; better differentiated tumor types express
higher levels of TFF3. TFF3 protein expression was asso-
ciated with expression of estrogen and progesterone re-
ceptors and with lower tumor grade, all of which are
features of well-differentiated invasive breast cancer.
These associations are consistent with our finding that
TFF3 is a protein of normal breast epithelium and suggest
that during the process of carcinogenesis and dediffer-
entiation TFF3 expression is lost from a subset of tumors.
Several functions have been ascribed to TFF3 on the
basis of laboratory studies, including inhibition of gastric
cancer cell growth,31 stimulation of angiogenesis in hu-
man umbilical vein endothelial cell and embryonic
chicken cell models,7 and stimulation of invasion of dif-
ferent types of cells.6 Our study was designed to deter-
mine whether the profile of expression of TFF3 in vivo
supports the hypothesis that TFF3 has these functions in
malignant breast tumors. The negative association be-
tween TFF3 expression and tumor grade would be con-
sistent with an inhibitory effect of TFF3 on breast cancer
cell growth because the number of mitotic bodies is one
of the three parameters that contribute to histologic tumor
grade. Evidence for a negative effect of TFF3 on prolifer-
ation derives also from the observation that it is not ex-
pressed in tumors characterized by high mitotic indices
and that it is absent from dividing cells within tumors that
do express TFF3. Further investigation found a strong
negative association between TFF3 protein expression
and expression of the proliferation biomarker Ki-67.
Our data support the hypothesis that TFF3 stimulates
angiogenesis in breast tumors. A positive association
was observed between TFF3 expression and microvessel
density, evaluated by the endothelial markers CD31 or
CD34. An association between TFF3 expression and mi-
crovessel density, evaluated by CD34 expression, has
been reported in gastric cancer.12 In contrast to the pres-
ent study, TFF3 expression was detected in endothelial
cells and in the nuclei of epithelial cells in gastric tumor
tissue.12 It is unclear if these anomalies are explained by
tissue or technical differences.
A striking finding of our study is the strength and con-
sistency of the association between TFF3 expression and
a more metastatic phenotype in invasive breast cancer.
TFF3 was expressed at higher levels in primary tumors
with associated metastasis, and the expression of TFF3
was higher in malignant cells that have metastasized
away from than in those within the primary tumor. Higher
TFF3 expression was associated with invasion of muscle,
the nipple, the neural sheath, and the lymphovasculature.
It was associated also with lymph node positivity, the
number of involved lymph nodes, and tumor cell escape
from axillary lymph nodes by capsular invasion. Consis-
tent with the hypothesis that tumor cells that express
higher levels of TFF3 are more invasive, tumor cells that
expressed high amounts of TFF3 were more likely to bedispersed through the stroma, whereas, in tumors with
lower TFF3 expression, tumor cells were present as clus-
ters within the stroma with the cells that expressed more
TFF3 concentrated at the periphery of the tumor cell
clusters.
Our data are consistent with a role of TFF3 in more than
one of the different stages of metastasis reviewed by
Nyuyen et al.32 During metastasis initiation, TFF3 en-
hances invasion by tumor cells of the stroma, in part by
stimulating their motility, and attracts a more supportive
stroma by increased angiogenesis. During metastasis
progression, TFF3 increases penetration of the neural
sheath and intravasation of the lymphovasculature. The
association between TFF3 expression and the coloniza-
tion of and subsequent escape from axillary lymph nodes
indicates continued involvement of TFF3 early during me-
tastasis virulence. The role of TFF3 protein expression in
breast cancer metastasis has not been studied previ-
ously, but TFF3 was identified as the second highest
ranking gene for the prediction of subsequent bony me-
tastasis in an expression microarray study of early breast
cancer,33 which is consistent with our finding that tumor
cells that express higher levels of TFF3 are more likely
to metastasize and suggests continued involvement of
TFF3 later during metastasis virulence to facilitate bone
colonization.
Interestingly, there appears to be a switch in the nor-
mal polarized secretion of TFF3 in invasive cancer. TFF3
is secreted toward the lumen away from the myoepithelial
cell layer and stroma in normal breast epithelial cell
monolayers (Figure 1, A–D). In well-differentiated breast
tumors, polarized TFF3 expression and secretion away
from the stroma into vestigial ductlike lumina is retained
(Figure 1, I–L, S, U, and V). In poorly differentiated tu-
mors, there appears to be a reversal in the epithelial cell
polarization with TFF3 concentrated at the stromal face of
the tumor cell clusters (Figure 1, M–O). This concentra-
tion of TFF3 toward the stroma suggests that TFF3 is
secreted from the tumor cells into the stroma, which
should allow it to exert any invasion-promoting effects in
an autocrine fashion or by a paracrine mechanism on
adjacent invasive malignant breast epithelial cells. Secre-
tion of TFF3 into the stroma would facilitate also paracrine
regulation of stromal cells, including potentially angio-
genic effects on endothelial cells within the stroma.
Functional data from in vitro experiments that support
our findings would be of value. It may be difficult to
substantiate directly our in vivo findings because the TFF3
cellular polarity may depend on the existence of the
structural architecture that is present within the breast
tissue. Individual malignant breast epithelial cells that
have potentially reversed polarity at the periphery of is-
lands of invasive malignant cells would have to be iso-
lated, and their polarity in vitro analyzed subsequently.
There are, however, elegant three-dimensional models of
breast cancer available in which cells become polarized.
It would be of interest to study different malignant breast
epithelial cells to investigate whether it is possible to
detect alterations in polarized secretion in cells with dif-
ferent invasive potential. The complexities inherent in rep-
lication of our observations in vitro do not detract from the
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polarity of TFF3 secretion changes with loss of tissue
architecture in some breast cancers.
TFF3 is expressed in normal breast epithelia, and we
suggest that TFF3 is regulated by estrogen and has
beneficial properties in normal breast epithelia. We
propose that, early during breast tumorigenesis, TFF3
retains its association with normal functionality of
breast epithelial cells and hence with differentiation.
Subsequently, with loss of breast tumor cell differenti-
ation, loss of normal intercellular contacts, and normal
epithelial cell polarization, expression of TFF3 with its
antimitotic, proangiogenic, and proinvasive properties is
subverted to promote cessation of growth, development
of tumor vasculature, intravasation and extravasation of
tumor cells via the lymphovasculatur, and locoregional
infiltration. An analogous change from beneficial to det-
rimental properties has been suggested for TFF1 in gas-
tric cancer.34
The simple model for the effects of estrogens in breast
cancer that accounts for the beneficial effects of estrogen
antagonists and aromatase inhibitors is that estrogens
control a set of genes that promote tumor progression
through a variety of pathways. Although numerous stud-
ies have identified estrogen-responsive genes, the key
genes that mediate the various effects of estrogens in
breast cancer have yet to be defined. TFF3 may be one
such mediator. Its expression is associated closely with
that of the estrogen receptor in breast tumors and is
induced by estrogens in breast cancer cells.20 The pres-
ent study shows that the level and pattern of expression
of TFF3 is consistent with a role in invasion and metasta-
sis. The paradox remains, however, for both the estrogen
receptor and TFF3 that they are expressed in normal
breast epithelial cells and contribute, therefore, to the
normal physiology of the breast epithelium but yet are
involved in the progression of cancer. For the estrogen
receptor that is a regulator of transcription, the repertoire
of genes whose expression is controlled by estrogen may
change during cellular transformation so that genes that
are not regulated in the normal epithelium become reg-
ulated in cancer.35,36 In the case of TFF3, a different
mechanism must be involved. It could be envisaged, for
example, that the switch from a beneficial to a malign
function may result from the breakdown of tissue archi-
tecture together with matrix remodeling which posits the
epithelial cells adjacent to fibroblasts, muscle, nerve, and
endothelial cells in an invasive tumor, whereas in the
normal breast, epithelial cells are surrounded exclusively
by myoepithelial cells. The importance of the compart-
mentalization provided by the myoepithelial cells is rec-
ognized widely and has led to them being referred to as
the tumor suppressor cells of the mammary gland. The
inversion of cell polarity observed in the present study will
exacerbate the effects of the breakdown in tissue archi-
tecture because it will facilitate direct secretion of TFF3
into the ectopic location of the tumor stroma in which it
will exert its biological effects in the stromal microenvi-
ronment.
The present study reinforces the view that TFF3 ex-
pression merits evaluation as a prognostic marker and asa predictive marker of response to therapy. Metastasis is
largely responsible for mortality in breast cancer, and
approved tests of prognosis include some genes thought
to be involved in the metastatic process. TFF3 could not
feature in currently approved gene expression profiles
used to predict disease progression (eg, oncotype.dx),
simply because it was not evaluated as a candidate
gene. The possibility that TFF3 may be a useful marker of
endocrine responsiveness in breast cancer was sug-
gested initially by our report that estrogen induces ex-
pression of TFF3 mRNA in estrogen-responsive cells,20
has been supported by gene expression studies that
found co-expression with estrogen receptor,21,22 and is
reinforced by the significant association between TFF3
protein and estrogen receptor expression reported in the
present study. In addition, TFF3 merits evaluation be-
cause it may be involved in mediating the adverse effects
of estrogen on tumor progression. Tamoxifen inhibits the
induction of TFF3 mRNA by estrogen,20 and it is probable
that the malign effects of TFF3 will be mitigated by adju-
vant endocrine therapy in women with hormone-respon-
sive cancers. The usefulness of TFF3 as a marker of
hormone responsiveness has not, however, been as-
sessed and requires evaluation. It may also merit evalu-
ation as a biomarker of response to other types of therapy
such as adjuvant bisphosphonate therapy,37 given the
predilection of tumors that express TFF3 to metastasize
to bone.33
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